175 related articles for article (PubMed ID: 38413795)
21. BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.
Zhang X; Guo X; Zhuo R; Tao Y; Liang W; Yang R; Chen Y; Cao H; Jia S; Yu J; Liao X; Li X; Fang F; Li G; Wu D; Xu Y; Li Z; Pan J; Wang J
Biochem Biophys Res Commun; 2022 May; 604():63-69. PubMed ID: 35299072
[TBL] [Abstract][Full Text] [Related]
22. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
23. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
24. The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35.
Liu PY; Tee AE; Milazzo G; Hannan KM; Maag J; Mondal S; Atmadibrata B; Bartonicek N; Peng H; Ho N; Mayoh C; Ciaccio R; Sun Y; Henderson MJ; Gao J; Everaert C; Hulme AJ; Wong M; Lan Q; Cheung BB; Shi L; Wang JY; Simon T; Fischer M; Zhang XD; Marshall GM; Norris MD; Haber M; Vandesompele J; Li J; Mestdagh P; Hannan RD; Dinger ME; Perini G; Liu T
Nat Commun; 2019 Nov; 10(1):5026. PubMed ID: 31690716
[TBL] [Abstract][Full Text] [Related]
25. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
26. An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.
Nagy Z; Seneviratne JA; Kanikevich M; Chang W; Mayoh C; Venkat P; Du Y; Jiang C; Salib A; Koach J; Carter DR; Mittra R; Liu T; Parker MW; Cheung BB; Marshall GM
Nat Commun; 2021 Mar; 12(1):1881. PubMed ID: 33767157
[TBL] [Abstract][Full Text] [Related]
27. MYCN induces neuroblastoma in primary neural crest cells.
Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
[TBL] [Abstract][Full Text] [Related]
28. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
[TBL] [Abstract][Full Text] [Related]
29. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
[TBL] [Abstract][Full Text] [Related]
30. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
[TBL] [Abstract][Full Text] [Related]
31. Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma.
Clark RA; Qiao J; Jacobson JC; Chung DH
Oncotarget; 2022; 13():32-45. PubMed ID: 35018218
[TBL] [Abstract][Full Text] [Related]
32. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
33. A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle.
Li HL; Dong LL; Jin MJ; Li QY; Wang X; Jia MQ; Song J; Zhang SY; Yuan S
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770809
[TBL] [Abstract][Full Text] [Related]
34. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.
Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G
Biochim Biophys Acta Gene Regul Mech; 2018 Mar; 1861(3):235-245. PubMed ID: 29408445
[TBL] [Abstract][Full Text] [Related]
35. SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.
Hu X; Liu R; Hou J; Peng W; Wan S; Xu M; Li Y; Zhang G; Zhai X; Liang P; Cui H
Oncogene; 2022 Sep; 41(37):4295-4306. PubMed ID: 35978151
[TBL] [Abstract][Full Text] [Related]
36. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
[TBL] [Abstract][Full Text] [Related]
37. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.
Yang Y; Wang S; Cai J; Liang J; Zhang Y; Xie Y; Luo F; Tang J; Gao Y; Shen S; Feng H; Li Y
Cell Oncol (Dordr); 2023 Feb; 46(1):133-143. PubMed ID: 36520365
[TBL] [Abstract][Full Text] [Related]
38. microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma.
He XY; Tan ZL; Mou Q; Liu FJ; Liu S; Yu CW; Zhu J; Lv LY; Zhang J; Wang S; Bao LM; Peng B; Zhao H; Zou L
Clin Cancer Res; 2017 Jun; 23(11):2905-2918. PubMed ID: 28003306
[No Abstract] [Full Text] [Related]
39. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
Sun Y; Liu PY; Scarlett CJ; Malyukova A; Liu B; Marshall GM; MacKenzie KL; Biankin AV; Liu T
Oncogene; 2014 Jun; 33(23):2987-94. PubMed ID: 23812427
[TBL] [Abstract][Full Text] [Related]
40. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]